Anúncio
Anúncio

SGMO

SGMO logo

Sangamo Therapeutics, Inc. Common Stock

0.45
USD
Patrocinado
0.00
-0.71%
09 de jan., 15:59 UTC -5
Encerrado
exchange

Pós-Mercado

0.45

0.00
+0.89%

Relatórios de Lucros SGMO

Rácio de surpresa positiva

SGMO separação 21 de 39 últimas estimativas.

54%

Próximo Relatório

Data do Próximo Relatório
16 de mar. de 2026
Estimate for Q4 25 (Revenue/ EPS)
$20.71M
/
-$0.07
Mudanças implicadas de Q3 25 (Revenue/ EPS)
+3463.86%
/
-36.36%
Mudanças implicadas de Q4 24 (Revenue/ EPS)
+174.22%
/
-36.36%

Sangamo Therapeutics, Inc. Common Stock earnings per share and revenue

On 06 de nov. de 2025, SGMO reported earnings of -0.11 USD per share (EPS) for Q3 25, missing the estimate of 0.00 USD, resulting in a -55100.00% surprise. Revenue reached 581.00 mil, compared to an expected 35.09 milhão, with a -98.34% difference. The market reacted with a -16.29% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 8 analistas forecast an EPS of -0.07 USD, with revenue projected to reach 20.71 milhão USD, implying an diminuir of -36.36% EPS, and aumentar of 3463.86% in Revenue from the last quarter.
FAQ
For Q3 2025, Sangamo Therapeutics, Inc. Common Stock reported EPS of -$0.11, missing estimates by -55100%, and revenue of $581.00K, -98.34% below expectations.
The stock price moved down -16.29%, changed from $0.55 before the earnings release to $0.46 the day after.
The next earning report is scheduled for 16 de mar. de 2026.
Based on 8 analistas, Sangamo Therapeutics, Inc. Common Stock is expected to report EPS of -$0.07 and revenue of $20.71M for Q4 2025.
Verificar FXEmpire's Earnings Calendar for today's list of reporting companies.
Anúncio